Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

In addition to Hitler, the entire Nazi leadership, the scientists who designed so many weapons, even in a very short range of ...

Quantum BioPharma Ltd (NASDAQ:QNTM) shares are rising Tuesday after the company announced positive clinical trial results for ...

In a survey, less than half of cancer patients and their family members said they were willing to participate in a clinical trial, and about a third of respondents said they had a positive perception ...

Clinical trial agreements (CTAs) form the foundation of any clinical research initiative, establishing the legal and operational framework ...

My firm has received a subject access request (SAR) from a client for whom we hold a large volume of files and correspondence. Given the volume of documentation, I’m going to struggle to comply with ...

WASHINGTON — The National Institutes of Health’s myriad divisions can start new work on mission-critical research, and continue working on ongoing studies, but cannot publicly communicate ...

Patent-Eligible Subject Matter refers to the types of inventions that can be legally patented. The criteria for patentability varies depending on the jurisdiction. In the United States ...

"Genprex doses first subject in expansion part of lung cancer gene therapy trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site ...

Subjects’ survival will also be monitored, with an interim analysis scheduled after the 25th patient reaches 18 weeks of follow-up. Tick here to opt out of curated industry news, reports, and event ...